指南与共识肿瘤 PET/CT

依据已发表推荐对弥漫性大B细胞淋巴瘤进行中期PET评估:Deauville 5分法与ΔSUVmax法的比较

Interim PET Evaluation in Diffuse Large B-Cell Lymphoma Using Published Recommendations: Comparison of the Deauville 5-Point Scale and the ΔSUVmax Method.
指南 / 共识 · J Nucl Med · 2020-05-08

该研究基于PET引导治疗侵袭性非霍奇金淋巴瘤试验中596例弥漫性大B细胞淋巴瘤患者的中期18F-FDG PET/CT数据,回顾性比较Deauville评分与ΔSUVmax法评估早期代谢反应。ΔSUVmax法在区分预后方面优于Deauville评分,无事件生存风险比为3.14(95%CI 2.22-4.46)对1.70(95%CI 1.29-2.24)。作者认为,考虑治疗强化时,以摄取高于肝脏为界值的Deauville评分不适当且可能对患者有害,ΔSUVmax相对降低≤66%可考虑作为替代标准。

要点

  • ΔSUVmax法在弥漫性大B细胞淋巴瘤中期PET预后区分上优于Deauville评分。
  • 无事件生存风险比:ΔSUVmax法3.14(95%CI 2.22-4.46),Deauville评分1.70(95%CI 1.29-2.24)。
  • 作者认为以摄取高于肝脏为界值的Deauville评分用于治疗强化决策不适当且可能有害。

核心结论

  • 考虑治疗强化时,当前使用的Deauville评分以摄取高于肝脏为界值似乎不适当,且与弥漫性大B细胞淋巴瘤患者的潜在伤害相关。
  • ΔSUVmax相对降低≤66%的标准可考虑作为替代。

研究设计与样本

  • 研究为PET引导治疗侵袭性非霍奇金淋巴瘤试验的事后分析,纳入609例弥漫性大B细胞淋巴瘤患者,其中596例原以ΔSUVmax法评估的中期PET扫描可用于Deauville评分的事后评估。
  • 采用Spearman秩相关系数分析两种方法的相关性,并评估分类一致性。
  • 采用Kaplan-Meier曲线和Cox回归评估按预设界值定义的患者亚组间生存差异。
  • 采用时间依赖性受试者工作特征曲线分析评估两种方法的区分性能。

主要发现

  • Deauville评分与ΔSUVmax法在基于中期PET的预后判断上存在差异。
  • ΔSUVmax法在区分性能上优于Deauville评分,很可能因为Deauville评分产生了大量假阳性决策。
  • 两种方法不依赖界值的区分性能均保持较低,但界值相关分析显示有希望的结果。
  • 两项分析均支持ΔSUVmax法,例如按中期PET反应分层时,无事件生存风险比ΔSUVmax法为3.14(95%CI 2.22-4.46),Deauville评分为1.70(95%CI 1.29-2.24)。

关键数值与推荐

  • Deauville评分定义中期PET结果不良的常用标准为摄取高于肝脏。
  • ΔSUVmax法定义中期PET扫描不良的标准为基线至中期PET分期的SUVmax相对降低≤66%。

临床怎么用

  • 作者认为,考虑治疗强化时,当前使用的Deauville评分以摄取高于肝脏为界值似乎不适当且与潜在伤害相关。
  • 作者认为,ΔSUVmax相对降低≤66%的标准可考虑作为替代。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The value of interim 18F-FDG PET/CT (iPET)-guided treatment decisions in patients with diffuse large B-cell lymphoma (DLBCL) has been the subject of much debate. This investigation focuses on a comparison of the Deauville score and the change-in-SUVmax (ΔSUVmax) approach-2 methods to assess early metabolic response to standard chemotherapy in DLBCL. Methods: Of 609 DLBCL patients participating in the PET-Guided Therapy of Aggressive Non-Hodgkin Lymphomas trial, iPET scans of 596 patients originally evaluated using the ΔSUVmax method were available for post hoc assessment of the Deauville score. A commonly used definition of an unfavorable iPET result according to the Deauville score is an uptake greater than that of the liver, whereas an unfavorable iPET scan with regard to the ΔSUVmax approach is characterized as a relative reduction of the SUVmax between baseline and iPET staging of less than or equal to 66%. We investigated the 2 methods' correlation and concordance by Spearman rank correlation coefficient and the agreement in classification, respectively. We further used Kaplan-Meier curves and Cox regression to assess differences in survival between patient subgroups defined by the prespecified cutoffs. Time-dependent receiver-operating-characteristic curve analysis provided information on the methods' respective discrimination performance. Results: Deauville score and ΔSUVmax approach differed in their iPET-based prognosis. The ΔSUVmax approach outperformed the Deauville score in terms of discrimination performance-most likely because of a high number of false-positive decisions by the Deauville score. Cutoff-independent discrimination performance remained low for both methods, but cutoff-related analyses showed promising results. Both favored the ΔSUVmax approach, for example, for the segregation by iPET response, where the event-free survival hazard ratio was 3.14 (95% confidence interval, 2.22-4.46) for ΔSUVmax and 1.70 (95% confidence interval, 1.29-2.24) for the Deauville score. Conclusion: When considering treatment intensification, the currently used Deauville score cutoff of an uptake above that of the liver seems to be inappropriate and associated with potential harm for DLBCL patients. The ΔSUVmax criterion of a relative reduction in SUVmax of less than or equal to 66% should be considered as an alternative.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Rekowski J, Hüttmann A, Schmitz C, et al. Interim PET Evaluation in Diffuse Large B-Cell Lymphoma Using Published Recommendations: Comparison of the Deauville 5-Point Scale and the ΔSUVmax Method. J Nucl Med. 2020. PMID: 32385164. doi:10.2967/jnumed.120.244145

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。